07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Novo Nordisk, Sun Pharmaceutical endocrine/metabolic news

The U.S. Supreme Court will hear oral arguments on Dec. 5 in the case of Caraco Pharmaceutical Laboratories Ltd. et al. v. Novo Nordisk A/S et al. The case will determine the proper scope of...
07:00 , Sep 1, 2011 |  BC Innovations  |  Targets & Mechanisms

Difficile defense

A team led by The University of Texas Medical Branch has identified the nitrosylation of Clostridium difficile toxins as a host defense mechanism that reduces cellular damage caused by the pathogen . 1 The researchers...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Company News

Novo Nordisk, Sun Pharmaceutical endocrine news

The U.S. sales of Prandin and PrandiMet amounted to about DKK1 billion ($178.9 million) in 2010. PrandiMet is a combination of repaglinide, a short-acting beta-cell stimulating meglitinide, and metformin. Under the Hatch-Waxman Act, FDA must...
07:00 , May 9, 2011 |  BC Week In Review  |  Company News

Novo Nordisk, Sun Pharmaceutical endocrine news

Novo Nordisk disclosed in its 1Q11 earnings that on March 28 the Supreme Court requested the U.S. Solicitor General to provide the view of the U.S. government on Novo's current Use Codes for the use...
07:00 , Jul 30, 2009 |  BC Innovations  |  Targets & Mechanisms

Depending on GHSR

Although a handful of biotech companies are pursuing ghrelin antagonists to treat obesity, the hormone target could also have a role in alcohol dependence, according to a team led by Swedish researchers. 1 Even though...
07:00 , Jul 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Addiction Metabotropic glutamate receptor subtype 5 (GRM5; mGluR5); homer homolog 2 (HOMER2); phosphoinositide 3-kinase (PI3K) Studies in mice suggest that inhibiting the mGluR5-HOMER2-PI3K signaling pathway...
07:00 , Jul 20, 2009 |  BC Week In Review  |  Company News

Forest Laboratories, Lundbeck, Sun Pharmaceutical neurology news

To settle a 2006 patent infringement suit over Forest's antidepressant Lexapro escitalopram, Forest granted Sun's Caraco Pharmaceutical Laboratories Ltd. (NYSE-A:CPD, Detroit, Mich.) subsidiary a license to market a generic version of the allosteric serotonin reuptake...
08:00 , Feb 4, 2002 |  BC Week In Review  |  Company News

Merck and Co. Inc. other research news

Scientists reported in Nature Medicine evidence that insulin mimetics may have use to treat obesity. Mice fed a high fat diet plus Cpd 2 gained less weight and had reduced body weight and adipose volume...